title: Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
abstract: Substituted guanines and pyrimidines were tested as inhibitors of cyclin B1/CDK1 and cyclin A3/CDK2 and soaked into crystals of monomeric CDK2. O6-Cyclohexylmethylguanine (NU2058) was a competitive inhibitor of CDK1 and CDK2 with respect to ATP (Ki values: CDK1, 5 +/- 1 microM; CDK2, 12 +/- 3 microM) and formed a triplet of hydrogen bonds (i.e., NH-9 to Glu 81, N-3 to Leu 83, and 2-NH2 to Leu 83). The triplet of hydrogen bonding and CDK inhibition was reproduced by 2,6-diamino-4-cyclohexylmethyloxy-5-nitrosopyrimidine (NU6027, Ki values: CDK1, 2.5 +/- 0.4 microM; CDK2, 1.3 +/- 0.2 microM). Against human tumor cells, NU2058 and NU6027 were growth inhibitory in vitro (mean GI50 values of 13 +/- 7 microM and 10 +/- 6 microM, respectively), with a pattern of sensitivity distinct from flavopiridol and olomoucine. These CDK inhibition and chemosensitivity data indicate that the distinct mode of binding of NU2058 and NU6027 has direct consequences for enzyme and cell growth inhibition.
authors.affiliation: Department of Chemistry, University of Newcastle, Newcastle upon Tyne, UK.
authors.forename: C E
authors.initials: CE
authors.lastname: Arris
authors.forename: F T
authors.initials: FT
authors.lastname: Boyle
authors.forename: A H
authors.initials: AH
authors.lastname: Calvert
authors.forename: N J
authors.initials: NJ
authors.lastname: Curtin
authors.forename: J A
authors.initials: JA
authors.lastname: Endicott
authors.forename: E F
authors.initials: EF
authors.lastname: Garman
authors.forename: A E
authors.initials: AE
authors.lastname: Gibson
authors.forename: B T
authors.initials: BT
authors.lastname: Golding
authors.forename: S
authors.initials: S
authors.lastname: Grant
authors.forename: R J
authors.initials: RJ
authors.lastname: Griffin
authors.forename: P
authors.initials: P
authors.lastname: Jewsbury
authors.forename: L N
authors.initials: LN
authors.lastname: Johnson
authors.forename: A M
authors.initials: AM
authors.lastname: Lawrie
authors.forename: D R
authors.initials: DR
authors.lastname: Newell
authors.forename: M E
authors.initials: ME
authors.lastname: Noble
authors.forename: E A
authors.initials: EA
authors.lastname: Sausville
authors.forename: R
authors.initials: R
authors.lastname: Schultz
authors.forename: W
authors.initials: W
authors.lastname: Yu
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D016203:CDC2 Protein Kinase / Q000037:antagonists & inhibitors* / Q000737:chemistry; D042846:CDC2-CDC28 Kinases; D018360:Crystallography, X-Ray; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D006860:Hydrogen Bonding; D008958:Models, Molecular; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry; D011687:Purines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D011743:Pyrimidines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011687:Purines; D011743:Pyrimidines; D017346:Protein Serine-Threonine Kinases; D016203:CDC2 Protein Kinase; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases